OraSure Technologies, Inc. (OSUR)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 2
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3, and avgDollarVolume20 is only $1.74M versus the $5M liquidity minimum.
Company overview
OraSure Technologies, Inc. specializes in oral fluid diagnostic solutions and specimen collection tools, operating through its Diagnostics and Molecular Solutions divisions. The company offers rapid tests for COVID-19, HIV, Hepatitis C, and Ebola, as well as genomic products and microbiome collection solutions. OraSure serves a diverse client base including clinical laboratories, hospitals, and public health organizations.
Fundamental
weakOraSure's fundamentals are challenged by negative profitability and cash flow, despite a strong liquidity position.
Operating results remain weak after the post‑pandemic revenue reset: trailing profitability and free cash flow are meaningfully negative, and recent GAAP profit benefited from a large non‑cash contingent‑consideration gain. Liquidity looks solid (large cash balance, minimal debt, and no going‑concern language in recent filings), reducing solvency risk but not yet fixing the earnings profile. EV/Sales looks modest largely because of cash; the core thesis still requires proof of sustainable growth and cash generation.
Sentiment
weakSentiment is mixed with no clear near-term catalysts, and media coverage remains flat.
The near-term narrative is dominated by the Aug. 5 Q2 results update (announced), with third-party coverage over the last ~14 days reading roughly flat/mixed (aggregator polarity_score ≈ +0.02) and highlighting limited near-term catalysts. Sentiment delta is indeterminate due to an empty 30–90d baseline pull at the filtered tier, and the legal/regulatory scan shows no active investigation signal.
Technical
weakThe stock is in a short-term downtrend with weak momentum, failing to meet liquidity requirements.
Score 2/5: OSUR is in a short-term downtrend with price below the SMA20, SMA50, EMA9, EMA21 and daily VWAP, while MACD remains below zero and ADX is elevated, signaling trend strength that currently favors sellers. The stock is still above its SMA200 and Williams %R is mildly oversold, so the chart is weak rather than fully broken.
You’re looking at 2026-08-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

